Efficacy of infliximab rescue therapy in patients with chronic refractory pouchitis: A multicenter study

Inflammatory Bowel Diseases

Volumn 18, Issue 5, 2012, Pages 812-817

  Barreiro de Acosta, M ^a   Garcia Bosch O ^b   Souto, R ^a   Manosa M ^c   Miranda, J ^d   Garcia Sanchez V ^e   Gordillo, J ^f   Chacon, S ^g   Loras, C ^h   Carpio, D ⁱ   Maroto, N ^j   Menchen L ^d   Rojas Feria, M ^k   Sierra, M ^l   Villoria, A ^m   Marin Jimenez, I ^d  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b Gastroenterology Unit   (Spain)

^c IrsiCaixa Aids Research Institute   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e Reina Sofía   (Argentina)

^f HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^g HOSPITAL MORALES MESEGUER   (Spain)

^h HOSPITAL MÚTUA DE TERRASSA   (Spain)

ⁱ CHOP   (Spain)

^j Manises   (Spain)

^k Valme   (Spain)

^l Virgen Blanca   (Spain)

^m PARC TAULÍ HOSPITAL UNIVERSITARI   (Spain)

more..

Author keywords

Chronic refractory pouchitis; Infliximab; Rescue therapy

Indexed keywords

AMINOSALICYLIC ACID; ANTIBIOTIC AGENT; AZATHIOPRINE; CIPROFLOXACIN; INFLIXIMAB; LOPERAMIDE; METHOTREXATE; METRONIDAZOLE; PROBIOTIC AGENT; RIFAXIMIN; STEROID;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; COLON RESECTION; DELAYED HYPERSENSITIVITY; DIARRHEA; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; ILEITIS; LUPUS LIKE SYNDROME; MALE; MULTICENTER STUDY; OPEN STUDY; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN TOXICITY; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; COLITIS, ULCERATIVE; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; POUCHITIS; PROCTOCOLECTOMY, RESTORATIVE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 81255146184     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21821     Document Type: Article

References (21)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417-429. (Pubitemid 34851835)
2. Nicholls RJ, Clark DN, Kelso L, et al. Nationwide linkage analysis in Scotland implicates age as the critical overall determinant of mortality in ulcerative colitis. Aliment Pharmacol Ther. 2010;31:1310-1321.
3. Parks AG, Nicholls RJ, Belliveau P. Proctocolectomy with ileal reservoir and anal anastomosis. Br J Surg. 1980;67:533-538. (Pubitemid 10056794)
4. Fazio VW, Ziv Y, Church JM, et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg. 1995;222:120-127.
5. Sandborn WJ, Tremaine WJ, Batts KP, et al. Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index. Mayo Clin Proc. 1994;69:409-415. (Pubitemid 24132681)
6. Shen B, Achkar J, Connor JT, et al. Modified Pouchitis Disease Activity Index: a simplified approach to the diagnosis of pouchitis. Dis Colon Rectum. 2003;46:748-753. (Pubitemid 36693394)
7. Holubar SD, Cima RR, Sandborn WJ, et al. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2010:CD001176.
8. Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005;128:1805-1811. (Pubitemid 40824691)
9. Colombel J, Ricart E, Loftus EV, et al. Management of Crohn's disease of the ileoanal pouch with infliximab. Am J Gastroenterol. 2003;98:2239-2244. (Pubitemid 37305365)
10. Haveran LA, Sehgal R, Poritz LS, et al. Infliximab and/or azathioprine in the treatment of Crohn's disease-like complications after IPAA. Dis Colon Rectum. 2011;54:15-20.
11. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A):5-36.
12. Domènech E, Esteve M, Gomollón F, et al. GETECCU-2005 recommendations for the use of infliximab (Remicade) in inflammatory bowel disease. Gastroenterol Hepatol. 2005;28:126-134. (Pubitemid 40470471)
13. Ferrante M, D'Haens G, Dewit O, et al. Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case series. Inflamm Bowel Dis. 2010;16:243-249.
14. Navaneethan U, Shen B. Pros and cons of antibiotic therapy for pouchitis. Expert Rev Gastroenterol Hepatol. 2009;3:547-559.
15. Ricart E, Panaccione R, Loftus EV, et al. Successful management of Crohn's disease of the ileoanal pouch with infliximab. Gastroenterology. 1999;117:429-432. (Pubitemid 29352953)
16. Kooros K, Katz AJ. Infliximab therapy in pediatric Crohn's pouchitis. Inflamm Bowel Dis. 2004;10:417-420. (Pubitemid 39029184)
17. Shen B, Remzi FH, Lavery IC, et al. Administration of adalimumab in the treatment of Crohn's disease of the ileal pouch. Aliment Pharmacol Ther. 2009;29:519-26.
18. Viscido A, Habib FI, Kohn A, et al. Infliximab in refractory pouchitis complicated by fistulae following ileo-anal pouch for ulcerative colitis. Aliment Pharmacol Ther. 2003;17:1263-1271. (Pubitemid 36693727)
19. Calabrese C, Gionchetti P, Rizzello F, et al. Short-term treatment with infliximab in chronic refractory pouchitis and ileitis. Aliment Pharmacol Ther. 2008;27:759-764. (Pubitemid 351490077)
20. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362:1383-1395.
21. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007;56:1226-1231. (Pubitemid 47300423)